Commercial development of exquisitely sensitive circulating tumor DNA diagnostics
| Reference number | |
| Coordinator | Lunds universitet - Institutionen för kliniska vetenskaper, Lund |
| Funding from Vinnova | SEK 2 000 000 |
| Project duration | January 2016 - March 2018 |
| Status | Completed |
Important results from the project
There is an urgent need for improved biomarkers to determine the disease state in cancer patients non-invasively. In this project we have now verified the market for our innovative products and services to measure circulating tumor DNA from a simple blood sample. As planned we have successfully completed all objectives of this VINN Verifiering project: SAGA Diagnostics AB was founded, we have market traction and paying customers, and we have secured significant seed round capital.
Expected long term effects
Following to our detailed project plan, we have verified our market assumptions, assessed the regulatory and legal requirements, confirmed the potential of our innovations and the market interest, protected our IPR, and pursued additional strategies for continued financing. We formed our spin-out company, now with seven employees, and are generating revenues and expanding operations. Within 5 to 10 years, ctDNA analyses have a real potential to reduce the cost of cancer care and improve patient survival and quality of life.
Approach and implementation
We completed all of our stated aims, which included market research, regulatory and legal requirements, competitive analysis and market verification, IPR protection, and securing of additional financing. We finished all of our milestones on time or ahead of schedule, and even accomplished additional tasks. Therefore, our implementation has followed our plan closely and we believe this project has been a tremendous success.